Pharma Equity Group A/S Cl A (PEG) — Net Asset Quality Index
Pharma Equity Group A/S Cl A (PEG) has a Net Asset Quality Index of 65.5% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of Dkr38.90 Million minus total liabilities of Dkr13.43 Million yields net assets of Dkr25.47 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Pharma Equity Group A/S Cl A (PEG) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Pharma Equity Group A/S Cl A Net Asset Quality Index Over Time (2008–2025)
This chart shows how Pharma Equity Group A/S Cl A's Net Asset Quality Index has evolved across 18 annual periods from 2008 to 2025. As of December 2025, the index stands at 65.5%, representing net assets of Dkr25.47 Million against total assets of Dkr38.90 Million DKK. See working capital to net assets of Pharma Equity Group A/S Cl A to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Pharma Equity Group A/S Cl A (2008–2025)
The table below presents the year-by-year Net Asset Quality Index for Pharma Equity Group A/S Cl A from 2008 to 2025, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see PEG company net worth.
| Year | Quality Index | Net Assets (DKK) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 65.5% | Dkr25.47 Million | Dkr38.90 Million | Dkr13.43 Million | ▼ -9.0 pp |
| 2024 | 74.5% | Dkr48.88 Million | Dkr65.61 Million | Dkr16.73 Million | ▲ +37.1 pp |
| 2023 | 37.4% | Dkr25.33 Million | Dkr67.74 Million | Dkr42.40 Million | ▼ -27.4 pp |
| 2022 | 64.8% | Dkr46.05 Million | Dkr71.07 Million | Dkr25.03 Million | ▼ -2.1 pp |
| 2021 | 66.9% | Dkr42.57 Million | Dkr63.65 Million | Dkr21.08 Million | ▲ +7.3 pp |
| 2020 | 59.5% | Dkr34.28 Million | Dkr57.58 Million | Dkr23.30 Million | ▼ -23.5 pp |
| 2019 | 83.1% | Dkr67.16 Million | Dkr80.84 Million | Dkr13.68 Million | ▼ -12.9 pp |
| 2018 | 96.0% | Dkr77.57 Million | Dkr80.84 Million | Dkr3.27 Million | ▼ -2.6 pp |
| 2017 | 98.6% | Dkr85.09 Million | Dkr86.30 Million | Dkr1.21 Million | ▲ +21.6 pp |
| 2016 | 77.0% | Dkr96.78 Million | Dkr125.75 Million | Dkr28.98 Million | ▼ -1.9 pp |
| 2015 | 78.8% | Dkr99.53 Million | Dkr126.25 Million | Dkr26.72 Million | ▼ -0.2 pp |
| 2014 | 79.0% | Dkr97.95 Million | Dkr123.97 Million | Dkr26.02 Million | ▲ +121.0 pp |
| 2013 | -42.0% | Dkr-105.44 Million | Dkr251.24 Million | Dkr356.68 Million | ▼ -49.2 pp |
| 2012 | 7.2% | Dkr36.39 Million | Dkr503.85 Million | Dkr467.46 Million | ▼ -8.5 pp |
| 2011 | 15.7% | Dkr79.67 Million | Dkr507.76 Million | Dkr428.10 Million | ▲ +5.0 pp |
| 2010 | 10.7% | Dkr53.06 Million | Dkr497.26 Million | Dkr444.20 Million | ▼ -60.0 pp |
| 2009 | 70.6% | Dkr53.47 Million | Dkr75.70 Million | Dkr22.24 Million | ▲ +49.1 pp |
| 2008 | 21.5% | Dkr56.25 Million | Dkr261.67 Million | Dkr205.42 Million | — |